The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV) use in disseminated choroid plexus papilloma (DCCP).
Mark Daniel Anderson
No relevant relationships to disclose
Brett James Theeler
No relevant relationships to disclose
Morris D. Groves
Consultant or Advisory Role - Genentech; Sanofi
Honoraria - Genentech; Merck; Sanofi
Research Funding - Celldex; Genentech; GlaxoSmithKline; Merck
Marta Penas-Prado
No relevant relationships to disclose
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck; Novartis
Honoraria - Merck; Novartis
Research Funding - Daiichi Sankyo